BioSpace News Archive

Ardelyx, Inc. provided an update on the company’s progress in 2023 and initial expectations for 2024.

Aclarion, Inc. announced that it has executed a strategic partnership agreement solidifying the previously signed non-binding Letter of Intent with Alphatec Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023, and issued 2024 financial guidance.

Aegle Therapeutics Corp., a leader in the development of novel extracellular vesicle (“EV”) therapies to treat rare and severe dermatological, including immuno-dermatological, conditions, today announced positive 12-week data for the first patient enrolled in a Phase 1/2a clinical trial of AGLE-102™ for the treatment of severe second-degree burns.

ChromaCode, Inc. today announced the signing of an early access agreement with Tennessee Oncology, a nationally recognized oncology practice with 35 clinical sites of care across Tennessee and in Northwest Georgia, to test the analytical and clinical performance of ChromaCode’s HDPCR non-small cell lung cancer (NSCLC) biomarker assay.

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on January 10, 2024 (https://emerginggrowth.com/conference/).

CorrectSequence Therapeutics’ CS-101 Successfully Cures One Patient of Transfusion-Dependent β-Thalassemia

Qvin™, the biotechnology research company that developed the first and only healthcare service that collects menstrual blood samples as an alternative to traditionally collected venous blood draws, announced FDA clearance of its Q-Pad™ and A1c Test.

PacBio announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million representing year-over-year growth of 113% and 56%, respectively.

AbbVie announced Phase 2 results showing adults with moderate to severe hidradenitis suppurativa who had previously failed anti-TNF therapy who received lutikizumab 300 mg every other week or 300 mg weekly achieved higher response rates than placebo in the primary endpoint of achieving HS Clinical Response at week 16.